Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03565991 · ClinicalTrials.gov registry record · Phase 2
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
NCT03565991 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 202 participants.
The verdict
NCT03565991, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
Study Summary
Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.
Interventions
- DRUG Talazoparib
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2023-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03565991
The ClinicalTrials.gov registry entry for NCT03565991 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Talazoparib is the first listed.
NCT03565991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03565991 about?
NCT03565991 is a clinical study titled "Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors". Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.
What is the current status of trial NCT03565991?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2018-06-18. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT03565991?
The interventions under investigation include: Talazoparib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT03565991?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.